Malvi Ajay, Khatib Mahalaqua Nazli, Balaraman Ashok Kumar, Roopashree R, Kaur Mandeep, Srivastava Manish, Barwal Amit, Siva Prasad G V, Rajput Pranchal, Syed Rukshar, Sharma Gajendra, Kumar Sunil, Singh Mahendra Pratap, Bushi Ganesh, Chilakam Nagavalli, Pandey Sakshi, Brar Manvinder, Mehta Rachana, Sah Sanjit, Gaidhane Abhay M, Shabil Muhammed, Daniel Afukonyo Shidoiku
Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Guwahati, 781101, India.
Division of Evidence Synthesis, Global Consortium of Public Health and Research, Datta Meghe Istitute of Higher Education, Wardha, India.
BMC Pulm Med. 2025 Jan 29;25(1):48. doi: 10.1186/s12890-025-03516-0.
Cannabis is the third most widely used psychoactive substance globally, and its consumption has been increasing, particularly with the growing trend of legalization for medicinal and recreational use. Recent studies have raised concerns about the potential impact of cannabis on respiratory health, specifically the risk of asthma, a significant public health concern. This systematic review aimed to consolidate research on the association between cannabis use and the risk of asthma.
A comprehensive search was conducted across PubMed, Embase, and Web of Science, covering studies published up to September 30, 2024. We included peer-reviewed observational studies evaluating the link between cannabis consumption and the risk of asthma diagnosis. Data synthesis employed a random-effects meta-analysis to account for heterogeneity. R statistical software (version 4.4) was used for statistical analyses.
The search yielded 8 relevant studies after screening 1,887 records. The pooled odds ratio (OR) for the association between cannabis consumption and the risk of asthma diagnosis was 1.31, 95% confidence interval (CI): 1.19-1.44, indicating greater odds of having asthma compared to non-users. Moderate heterogeneity was observed (I² = 46%), and sensitivity analysis confirmed the robustness of the findings.
This systematic review and meta-analysis identifies a significant association between cannabis use and greater odds of having asthma. These findings emphasize the importance of raising awareness about the potential respiratory risks associated with cannabis use. Future research should prioritize identifying moderating factors, such as the frequency and mode of cannabis consumption, to enhance understanding of this association and provide a stronger evidence base for potential public health interventions.
Not applicable.
大麻是全球使用第三广泛的精神活性物质,其消费量一直在增加,尤其是随着药用和娱乐用大麻合法化趋势的不断发展。最近的研究引发了人们对大麻对呼吸系统健康潜在影响的担忧,特别是哮喘风险,这是一个重大的公共卫生问题。本系统评价旨在整合关于大麻使用与哮喘风险之间关联的研究。
在PubMed、Embase和Web of Science数据库中进行了全面检索,涵盖截至2024年9月30日发表的研究。我们纳入了评估大麻消费与哮喘诊断风险之间联系的同行评审观察性研究。数据合成采用随机效应荟萃分析来处理异质性。使用R统计软件(版本4.4)进行统计分析。
在筛选了1887条记录后,检索得到8项相关研究。大麻消费与哮喘诊断风险之间关联的合并比值比(OR)为1.31,95%置信区间(CI):1.19 - 1.44,表明与非使用者相比,患哮喘的几率更高。观察到中度异质性(I² = 46%),敏感性分析证实了研究结果的稳健性。
本系统评价和荟萃分析确定了大麻使用与患哮喘几率增加之间存在显著关联。这些发现强调了提高对大麻使用相关潜在呼吸风险认识的重要性。未来的研究应优先确定调节因素,如大麻消费的频率和方式,以增进对这种关联的理解,并为潜在的公共卫生干预措施提供更有力的证据基础。
不适用。